Venmax Drugs And Pharmaceuticals Ltd
BSE: 531015
values in crores
Revenue & Profit Trend
in croresRevenueExpenditureNet Profit
Margin Trend
percentageOPM %NPM %
| Period | Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|---|---|---|
| INCOME | |||||||
| Revenue | 3.94+154.1% | 1.55+17.7% | 1.32+8.9% | 1.21+263.7% | 0.33+67.2% | 0.20+16.4% | 0.17 |
| Other Income | 0.09+34.8% | 0.07 | 0.00 | 0.00-100.0% | 1.02 | — | — |
| Total Income | 4.04+149.0% | 1.62+22.9% | 1.32+8.9% | 1.21-10.7% | 1.36+581.4% | 0.20+16.4% | 0.17 |
| EXPENSES | |||||||
| Expenditure | 3.93+149.2% | 1.58+23.9% | 1.27+8.6% | 1.17+101.8% | 0.58-16.4% | 0.69+46.0% | 0.48 |
| Tax | -0.00-125.9% | 0.01-48.1% | 0.02 | 0.00+100.0% | -0.00 | 0.00 | 0.00 |
| PROFIT | |||||||
| PBT | 0.10+143.4% | 0.04-4.9% | 0.05+20.6% | 0.04-95.2% | 0.77+256.5% | -0.49-62.8% | -0.30 |
| Net Profit | 0.11+234.0% | 0.03+32.1% | 0.02-35.0% | 0.04-95.2% | 0.78+257.2% | -0.49-62.3% | -0.30 |
| KEY METRICS | |||||||
| OPM % | 0.34%+1.91pp | -1.57%-5.11pp | 3.54%+0.36pp | 3.18%+77.31pp | -74.13% | — | — |
| NPM % | 2.66%+0.68pp | 1.98%+0.14pp | 1.84%-1.25pp | 3.09%-54.30pp | 57.39%+157.39pp | -100.00% | -100.00% |
| EPS | 0.21+320.0% | 0.05+0.0% | 0.05-28.6% | 0.07-95.3% | 1.49+256.8% | -0.95-63.8% | -0.58 |
Corporate Events
Board MeetingVENMAX
20267Feb
Board Meeting
Consider and approve the Unaudited Financial Results For The…
BSE Filing ↗ Board MeetingVENMAX
202512Nov
Board Meeting
Consider and approve the un-audited financial results for th…
BSE Filing ↗ Board MeetingVENMAX
20258Feb
Board Meeting
Un-audited Financial Results, Limited Review Report, Any oth…
BSE Filing ↗ Board MeetingVENMAX
202411Nov
Board Meeting
Un-audited Financial Results, Limited Review Report, Any oth…
BSE Filing ↗ Board MeetingVENMAX
202422Aug
Board Meeting
Consideration and approval of the Notice of the ensuing Thir…
BSE Filing ↗ Board MeetingVENMAX
202414May
Board Meeting
consider and approve the Audited Standalone Financial Result…
BSE Filing ↗